A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
China
Beijing Gobroad Boren Hospital, Beijing, Beijing Municipality The Affiliated Hospital of Northwest University Xi'an No.3 Hospital, Xi’an, Shanxi The first affiliated hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Last updated November 2024